VivoSeq
Other

Driving

0

Pipeline Programs↗

2

Active Trials↗

11

Companies Involved↗

Driving is an early-stage landscape with 0 programs across 11 companies. The most active players are Eli Lilly, Utrecht Institute for Pharmaceutical Sciences, Taisho Pharmaceutical Co., Ltd..

Intelligence

Pipeline Metrics

Competitive Density

10/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

92/100

Attrition Rate

8/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Eli Lilly logo

Eli Lilly

0 programs

PreclinicalU

Utrecht Institute for Pharmaceutical Sciences

0 programs

PreclinicalT

Taisho Pharmaceutical Co., Ltd.

0 programs

PreclinicalN

Neurana Pharmaceuticals, Inc.

0 programs

PreclinicalMerck & Co. logo

Merck & Co.

0 programs

PreclinicalP

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

26

clinical trials

Completed22 · 85%
Recruiting2 · 8%
Withdrawn1 · 4%
Terminated1 · 4%

Clinical Trials

Trial Activity

26 trials

Exploring Parameters of Driving Simulation in Relation to Drug Holidays in ADHD Patients
Recruiting·—·N/A·NCT06910605·26 enrolled
The Effects of Cannabidiol on the Driving Performance of Healthy Adults by Dose and Sex
Recruiting·WWest Virginia University·Phase 1·NCT06686914·300 enrolled
Effect of Armodafinil on Simulated Driving
Completed·UUniversity of Florida·Phase 1·NCT02468856·12 enrolled
Effects of Ramelteon on Driving Ability
Completed·UUtrecht Institute for Pharmaceutical Sciences·Phase 1·NCT00319215·30 enrolled
Impact of Cholinesterase Inhibitors on Driving Ability in Healthy Older Adults
Completed·SSunnybrook Health Sciences Centre·Phase 4·NCT00482001·22 enrolled
A Study to Evaluate Next Day Effects of TS-142 on Driving Performance in Healthy Subjects
Completed·TTaisho Pharmaceutical Co., Ltd.·Phase 1·NCT04696952·61 enrolled
The Effects of Cannabidiol on the Driving Ability of Healthy Adults
Completed·WWest Virginia University·Phase 2·NCT04590495·40 enrolled
Development of a Valid Test Battery for Assessing Driving Ability When Influenced by Drugs.
Completed·SSt. Olavs Hospital·N/A·NCT00967421·20 enrolled
Driving Simulation to Assess Non-Sedative Effects of Tolperisone
Completed·NNeurana Pharmaceuticals, Inc.·Phase 1·NCT03353922·35 enrolled
The Effects of Lasmiditan on Simulated Driving Performance - Healthy Participants
Completed·Eli Lilly logoEli Lilly·Phase 1·NCT03012334·90 enrolled
A Study to Evaluate Next Day Effects of MK-4305 on Driving Performance (MK-4305-035 AM1)
Completed·Merck & Co. logoMerck & Co.·Phase 1·NCT01311882·28 enrolled
Effect of Vyvanse on Driving in Young Adults With ADHD
Completed·MMassachusetts General Hospital·Phase 4·NCT00801229·75 enrolled
Method of Assessment of Driving Ability in Patients Suffering From Wakefulness Pathologies.
Completed·UUniversity Hospital, Caen·N/A·NCT01231828·55 enrolled
Study to Assess the Effect of Gabapentin Enacarbil on Simulated Driving in Healthy Subjects
Completed·XXenoPort, Inc.·Phase 1·NCT01411124·36 enrolled
Next-Day Residual Effects of Gabapentin, Diphenhydramine and Triazolam on Simulated Driving Performance in Normal Volunteers
Completed·PPfizer's Upjohn has merged with Mylan to form Viatris Inc.·Phase 3·NCT01888497·59 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)